Salem et al., 2017 - Google Patents
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancersSalem et al., 2017
View HTML- Document ID
- 2553288006009554743
- Author
- Salem M
- Weinberg B
- Xiu J
- El-Deiry W
- Hwang J
- Gatalica Z
- Philip P
- Shields A
- Lenz H
- Marshall J
- Publication year
- Publication venue
- Oncotarget
External Links
Snippet
Tumor sidedness has emerged as an important prognostic and predictive factor in the treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right- sided colon cancers have a worse prognosis than those with left-sided colon or rectal …
- 210000001072 Colon 0 title abstract description 90
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Salem et al. | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers | |
| Tie et al. | Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies | |
| Liu et al. | Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations | |
| Imamura et al. | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers | |
| Iyer et al. | Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer | |
| Vizoso et al. | Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR | |
| Voss et al. | Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions | |
| Tokunaga et al. | The impact of ARID1A mutation on molecular characteristics in colorectal cancer | |
| Narayan et al. | Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations | |
| Haley et al. | Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers | |
| Rachakonda et al. | Somatic mutations in exocrine pancreatic tumors: association with patient survival | |
| Park et al. | EGFR exon 20 insertion/duplication mutations characterize fibrous hamartoma of infancy | |
| Voutsina et al. | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer | |
| Gleeson et al. | Lung cancer adrenal gland metastasis: optimal fine‐needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next‐generation sequencing | |
| Estrella et al. | Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing | |
| Li et al. | Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing | |
| Singh et al. | Molecular characterization and therapeutic targeting of colorectal cancers harboring receptor tyrosine kinase fusions | |
| Normanno et al. | Role of molecular genetics in the clinical management of cholangiocarcinoma | |
| Jones et al. | Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma | |
| Liu et al. | The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer | |
| Boucai et al. | Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy | |
| Rodriguez et al. | IDH1 and IDH2 mutations in lung adenocarcinomas: evidences of subclonal evolution | |
| Kruger et al. | Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study | |
| Goel | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream | |
| Oiwa et al. | Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis |